The aim of this study was to conduct 3 literature reviews to examine the impact of atopic dermatitis (AD) and chronic hand eczema (CHE) on health-related quality of life (HRQoL) compared with other chronic conditions by comparing reported utility scores of 4 commonly used generic HRQoL instruments. A systematic search was performed using PubMed, ScienceDirect, MEDLINE, EMBASE, Health Technology Assessment database, and ScHARRHUD. Inclusion criteria included, but were not limited to, patients of any age, studies from any location, publications reporting utility data based on EuroQoL 5 dimensions, the EuroQoL 5-dimension Visual Analog Scale, the Short-Form Health Survey, and the Short-Form 6 Dimensions in the English language. Inclusion criteria were met by 16 articles for AD, 25 articles for chronic conditions, and 9 articles for CHE. The findings of this review highlight that the disutility and loss in HRQoL of patients with AD and CHE are similar to or higher than other chronic conditions, such as cancer or hepatitis.
Get full access to this article
View all access options for this article.
References
1.
DiepgenTL, AndersenKE, ChosidowO, et al.Guidelines for diagnosis, prevention and treatment of hand eczema. J German Soc Dermatol, 2014; e1–e22.
2.
BoguniewiczM, FonacierL, Guttman-YasskyE, et al.Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol, 2018; 120:10–22.
3.
HowellMD, ParkerML, MustelinT, et al.Past, present, and future for biologic intervention in atopic dermatitis. Allergy, 2015; 70:887–896.
4.
Silvestre SalvadorJF, Romero-PerezD, Encabo-DuranB. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol, 2017; 27(7):78–88.
5.
LeeHH, PatelKR, SingamV, et al.A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol, 2019; 80(6):1526–1532.
6.
DeckersIA, McLeanS, LinssenS, et al.Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLoS One, 2012; 7(7):e39803.
7.
Chiesa FuxenchZC, BlockJK, BoguniewiczM, et al.Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol, 2019; 139:583–590.
8.
BarbarotS, AuziereS, GadkariA, et al.Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy, 2018; 73(6):1284–1293.
EckertL, GuptaS, AmandC, et al.The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol, 2017; 78(1):54–61.e51.
11.
SilverbergJI, GelfandJM, MargolisDJ, et al.Patient burden and quality of life in atopic dermatitis in US adults. Ann Allergy Asthma Immunol, 2018; 121:340–347.
12.
SimonD, WollenbergA, RenzH, et al.Atopic dermatitis: Collegium Internationale Allergologicum (CIA) update 2019. Int Arch Allergy Immunol, 2019; 178:207–218.
13.
AndersonRT, RajagopalanR. Effects of allergic dermatosis on health-related quality of life. Curr Allergy Asthma Rep, 2001; 1(4):309–315.
14.
WhitleyJ, EmirB, SeitzmanR, et al.The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin, 2016; 32(10):1645–1651.
15.
YuSH, AttarianH, ZeeP, et al.Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis, 2016; 27(2):50–58.
16.
AndersenYMF, EgebergA, SkovL, et al.Comorbidities of atopic dermatitis: beyond rhinitis and asthma. Curr Dermatol Rep, 2017; 6(1):35–41.
17.
DalgardFJ, GielerU, Tomas-AragonesL, et al.The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Investig Dermatol, 2015; 135(4):984–991.
18.
AbuabaraK, YeM, McCullochCE, et al.Clinical onset of atopic eczema: results from 2 nationally representative British birth cohorts followed through midlife. J Allergy Clin Immunol, 2019; 144:710–719.
19.
SilverbergJI. Health care utilization, patient costs, and access to care in US adults with eczema: a population-based study. JAMA Dermatol, 2015; 151(7):743–752.
20.
The Eczema Society of Canada. About hand eczema. Available at: https://eczemahelp.ca/hand-eczema/. Published 2019. Accessed September26, 2019.
21.
DiepgenTL, AgnerT, AbererW, et al.Management of chronic hand eczema. Contact Dermatitis, 2007; 57(4):203–210.
22.
NielsenNH, LinnebergA, MenneT, et al.The association between contact allergy and hand eczema in 2 cross-sectional surveys 8 years apart: the Copenhagen allergy study. Contact Dermatitis, 2002; 47(2):71–77.
23.
BarrettA, Hahn-PedersenJ, KraghN, et al.Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient, 2019; 12:445–459.
24.
FowlerJF, GhoshA, SungJ, et al.Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. JAAD, 2006; 54(3):448–457.
25.
CazzanigaS, ApfelbacherC, DiepgenT, et al.Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data. Br J Dermatol, 2018; 178(1):229–237.
26.
ElstonD, AhmedD, WatskyK, et al.Hand dermatitis. J Am Acad Dermatol, 2002; 47(2):291–299.
27.
MollerupA, VeienNK, JohansenJD. Chronic hand eczema—self-management and prognosis: a study protocol for a randomised clinical trial. BMC Dermatol, 2012; 12:6.
28.
ManuelDG, SchultzSE, KopecJA. Measuring the health burden of chronic disease and injury using health adjusted life expectancy and the Health Utilities Index. J Epidemiol Community Health, 2002; 56:843–850.
29.
US Department of Health and Human Services. An Assessment of the State of the Art for Measuring Burden of Illness. Washington, DC: US Department of Health and Human Services; 2011.
30.
HigginsJ, AltmanD, Sterne JThe Cochrane Collaboration. In: Chapter 8: Assessing Risk of Bias in Included Studies, 2011.
31.
Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. York: Centre for Reviews and Dissemination, University of York;. 2009.
HillenM, MedendorpN, DaamsJ, et al.Appendix C—Adapted Newcastle-Ottawa Scale for Evaluating Cross-sectional/Survey Studies. In patient-driven second opinions in oncology: a systematic review. Oncologist, 2017; 22:1197–1211.
35.
SheaBJ, ReevesBC, WellsG, et al.AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017; 358:j4008.
36.
LiberatiA, AltmanDG, TetzlaffJ, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol, 2009; 62:e1–e34.
PooleCD, ChambersC, SidhuMK, et al.Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study. Br J Dermatol, 2009; 161(6):1335–1340.
42.
PooleCD, ChambersC, AllsoppR, et al.Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs topical corticosteroids. J Eur Acad Dermatol Venereol, 2010; 24(6):674–678.
43.
VietriJ, NybergF, VarolN. The impact of severity of atopic dermatitis on patient-reported outcomes of adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol, 2017; 76(6):AB254.
44.
LeeSH, LeeSH, LeeSY, et al.Psychological health status and health-related quality of life in adults with atopic dermatitis: a nationwide cross-sectional study in South Korea. Acta Derm Venereol, 2018; 98(1):89–97.
45.
LangenbruchA, RadtkeM, FranzkeN, et al.Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol, 2014; 28(6):719–726.
46.
VindingGR, KnudsenKM, EllervikC, et al.Self-reported skin morbidities and health-related quality of life: a population-based nested case-control study. Dermatology, 2014; 228(3):261–268.
47.
LundbergL, JohannessonM, SilverdahlM, et al.Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol, 2000; 80(6):430–434.
48.
KiebertG, SorensenSV, RevickiD, et al.Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol, 2002; 41(3):151–158.
49.
EckertL, GuptaS, AmandC, et al.Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol, 2017; 77(2):274–279.e273.
50.
SilverbergJI, GelfandJM, MargolisDJ. Health utility scores of atopic dermatitis in US adults. J Allergy Clin Immunol Pract, 2019; 7(4):1246–1252.e1241.
51.
SilverbergJI, GelfandJM, MargolisDJ, et al.Validation and interpretation of Short Form 12 and comparison with Dermatology Life Quality Index in atopic dermatitis in adults. J Invest Dermatol, 2019; 139(10):2090–2097.e2093.
KüsterD, HaufeE, RethbergC, et al.Health utilities for controlled and uncontrolled chronic hand eczema in healthcare employees. Contact Dermatitis, 2018; 78(1):18–27.
54.
CoretsiPA, ScaloneL, BelisariA, et al.Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis, 2014; 70(3):158–168.
55.
DibenedettiD, BaranowskiE, ZeltS, et al.Assessing United States patient and dermatologist experiences with severe chronic hand eczema. J Clin Aesthet Dermatol, 2015; 8(11):19–27.
56.
van GilsRF, BosmansJE, BootCR, et al.Economic evaluation of an integrated care programme for patients with hand dermatitis. Contact Dermatitis, 2013; 69(3):144–152.
57.
WójcikA, MłyńczakK, DobrowolskaI, et al.PSY99 systematic review of EQ-5D based utility scores in leukemias. Value Health, 2016; 19(7):A592.
58.
MlynczakK, WojcikA, DobrowolskaI, et al.Systematic review of health state utilities based on the EQ-5D in studies of lymphomas. Value Health, 2016; 19(7):A593.
59.
GolickiD, WójcikA, MłyńczakK, et al.PSY103 systematic review of EQ-5D based health state utility values in multiple myeloma. Value Health, 2016; 19(7):A593.
60.
DyerMT, GoldsmithKA, SharplesLS, et al.A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes, 2010; 8:13.
61.
MatchamF, ScottIC, RaynerL, et al.The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum, 2014; 44(2):123–130.
62.
AlhajiMM, TanJ, HamidMR, et al.Determinants of quality of life as measured with variants of SF-36 in patients with predialysis chronic kidney disease. Saudi Med J, 2018; 39(7):653–661.
63.
HarrisonMJ, DaviesLM, BansbackNJ, et al.The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol, 2008; 35(4):592–602.
64.
SmithDW, DaviesEW, WissingerE, et al.A systematic literature review of cardiovascular event utilities. Expert Rev Pharmacoecon Outcomes Res, 2013; 13(6):767–790.
65.
MøllerAH, ErntoftS, VindingGR, et al.A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D–derived utility values. Patient Relat Outcome Meas, 2015; 7(6):167–177.
66.
AliFM, CuevaAC, VyasJ, et al.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol, 2017; 176(3):577–593.
67.
MobergC, AlderlingM, MedingB. Hand eczema and quality of life: a population-based study. Br J Dermatol, 2009; 161(2):397–403.
68.
VakhariaPP, ChopraR, SilverbergJI. Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials. Am J Clin Dermatol, 2018; 19(1):15–22.
69.
SimpsonEL, KeckLE, ChalmersJR, et al.How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies. J Allergy Clin Immunol, 2012; 130(1):137–144.
70.
SilverbergJI, ThyssenJP, PallerAS, et al. University of Zurich. Zurich Open Repository and Archive Website. What's in a name? Atopic dermatitis or atopic eczema, but not eczema alone. Available at: https://www.zora.uzh.ch/id/eprint/140844/8/lone.pdf. Published 2017. Accessed January20, 2020.
